Quick Take
Centogene (OTC:CNTG) has filed to raise gross proceeds of $69 million from a U.S. IPO, according to an F-1 registration statement.
The firm has developed a platform for the identification of rare genetic diseases.
CNTG is growing smartly in a favorable industry segment, although the company is generating increasing operating losses.
I’ll provide an update when we learn more IPO details from management.
Company & Technology
Rostock, Germany-based Centogene was founded in 2006 and has developed a rare diseases platform with over 2 billion weighted data points.
Management is headed